B-intervention	0	4	Dose
I-intervention	4	5	-
I-intervention	5	16	intensified
I-intervention	17	27	epirubicin
O	28	34	versus
B-control	35	43	standard
I-control	43	44	-
I-control	44	48	dose
I-control	49	59	epirubicin
I-control	59	60	/
I-control	60	76	cyclophosphamide
O	77	85	followed
O	86	88	by
O	89	92	CMF
O	93	95	in
B-eligibility	96	102	breast
I-eligibility	103	109	cancer
I-eligibility	110	118	patients
I-eligibility	119	123	with
I-eligibility	124	126	10
I-eligibility	127	129	or
I-eligibility	130	134	more
I-eligibility	135	143	positive
I-eligibility	144	149	lymph
I-eligibility	150	155	nodes
O	155	156	:
O	157	164	results
O	165	167	of
O	168	169	a
O	170	180	randomised
O	181	186	trial
O	187	188	(
O	188	192	GABG
O	192	193	-
O	193	195	IV
O	196	197	E
O	197	198	-
O	198	200	93
O	200	201	)
O	202	203	-
O	204	207	the
O	208	214	German
O	215	223	Adjuvant
O	224	230	Breast
O	231	237	Cancer
O	238	243	Group
O	243	244	.

O	245	247	To
O	248	255	compare
O	256	260	dose
O	260	261	-
O	261	272	intensified
O	273	283	epirubicin
O	284	295	monotherapy
O	296	300	with
O	301	302	a
O	303	311	standard
O	312	322	sequential
O	323	330	regimen
O	330	331	,
O	332	340	patients
O	341	345	with
O	346	353	primary
O	354	360	breast
O	361	367	cancer
O	368	371	and
O	372	373	>
O	374	376	or
O	377	378	=
O	378	380	10
O	381	389	involved
O	390	398	axillary
O	399	404	nodes
O	405	409	were
O	410	420	randomised
O	421	423	to
O	424	430	either
O	431	435	four
O	436	438	21
O	438	439	-
O	439	442	day
O	443	449	cycles
O	450	452	of
O	453	463	epirubicin
O	464	467	120
O	468	470	mg
O	470	471	/
O	471	472	m
O	472	473	(
O	473	474	2
O	474	475	)
O	476	477	(
O	477	481	E120
O	481	482	;
O	483	484	n
O	484	485	=
B-intervention-participants	485	488	202
O	488	489	)
O	490	492	or
O	493	497	four
O	498	500	21
O	500	501	-
O	501	504	day
O	505	511	cycles
O	512	514	of
O	515	525	epirubicin
O	526	528	90
O	529	531	mg
O	531	532	/
O	532	533	m
O	533	534	(
O	534	535	2
O	535	536	)
O	537	541	plus
O	542	558	cyclophosphamide
O	559	562	600
O	563	565	mg
O	565	566	/
O	566	567	m
O	567	568	(
O	568	569	2
O	569	570	)
O	571	572	(
O	572	574	EC
O	574	575	)
O	576	584	followed
O	585	587	by
O	588	593	three
O	594	596	28
O	596	597	-
O	597	600	day
O	601	607	cycles
O	608	610	of
O	611	627	cyclophosphamide
O	627	628	,
O	629	641	methotrexate
O	642	645	and
O	646	647	5
O	647	648	-
O	648	660	fluorouracil
O	661	662	(
O	662	665	CMF
O	665	666	;
O	667	668	n
O	668	669	=
B-control-participants	669	672	209
O	672	673	)
O	673	674	.

O	675	687	Simultaneous
O	688	696	hormonal
O	697	706	treatment
O	707	710	was
O	711	718	applied
O	719	721	in
O	722	726	both
O	727	731	arms
O	731	732	.

O	733	735	At
O	736	737	5
O	738	743	years
O	743	744	'
O	745	751	median
O	752	758	follow
O	758	759	-
O	759	761	up
O	761	762	,
O	763	766	the
B-outcome	767	768	5
I-outcome	768	769	-
I-outcome	769	773	year
I-outcome	774	779	event
I-outcome	779	780	-
I-outcome	780	784	free
I-outcome	785	793	survival
I-outcome	794	795	(
I-outcome	795	798	EFS
I-outcome	798	799	)
I-outcome	800	805	rates
O	806	810	were
B-iv-bin-percent	811	813	47
I-iv-bin-percent	813	814	.
I-iv-bin-percent	814	815	7
I-iv-bin-percent	815	816	%
O	817	818	(
O	818	820	95
O	820	821	%
O	822	832	confidence
O	833	841	interval
O	842	843	[
O	843	845	CI
O	845	846	]
O	846	847	,
O	848	850	40
O	850	851	.
O	851	852	2
O	852	853	-
O	853	855	55
O	855	856	.
O	856	857	2
O	857	858	%
O	858	859	)
O	860	863	for
O	864	868	E120
O	869	872	and
B-cv-bin-percent	873	875	45
I-cv-bin-percent	875	876	.
I-cv-bin-percent	876	877	9
I-cv-bin-percent	877	878	%
O	879	880	(
O	880	882	38
O	882	883	.
O	883	884	5
O	884	885	-
O	885	887	53
O	887	888	.
O	888	889	3
O	889	890	%
O	890	891	)
O	892	895	for
O	896	898	EC
O	898	899	-
O	899	902	CMF
O	902	903	.

O	904	908	E120
O	909	912	was
O	913	915	as
O	916	925	effective
O	926	928	as
O	929	931	EC
O	931	932	-
O	932	935	CMF
O	936	940	with
O	941	947	regard
O	948	950	to
B-outcome	951	954	EFS
O	955	956	(
O	956	962	hazard
O	963	968	ratio
O	969	970	[
O	970	972	HR
O	972	973	]
O	974	977	for
O	978	982	E120
O	983	989	versus
O	990	992	EC
O	992	993	-
O	993	996	CMF
O	997	998	1
O	998	999	.
O	999	1001	04
O	1001	1002	;
O	1003	1005	95
O	1005	1006	%
O	1007	1009	CI
O	1009	1010	,
O	1011	1012	0
O	1012	1013	.
O	1013	1015	79
O	1015	1016	-
O	1016	1017	1
O	1017	1018	.
O	1018	1020	36
O	1020	1021	;
O	1022	1023	p
O	1023	1024	=
O	1024	1025	0
O	1025	1026	.
O	1026	1028	79
O	1028	1029	)
O	1030	1033	and
B-outcome	1034	1041	overall
I-outcome	1042	1050	survival
O	1051	1052	(
O	1052	1054	HR
O	1055	1056	1
O	1056	1057	.
O	1057	1059	06
O	1059	1060	;
O	1061	1063	95
O	1063	1064	%
O	1065	1067	CI
O	1068	1069	0
O	1069	1070	.
O	1070	1072	77
O	1072	1073	-
O	1073	1074	1
O	1074	1075	.
O	1075	1077	46
O	1077	1078	;
O	1079	1080	p
O	1080	1081	=
O	1081	1082	0
O	1082	1083	.
O	1083	1085	72
O	1085	1086	)
O	1086	1087	.

O	1088	1091	The
O	1092	1096	data
O	1097	1108	demonstrate
O	1109	1113	that
O	1114	1115	4
O	1116	1122	cycles
O	1123	1125	of
O	1126	1130	dose
O	1130	1131	-
O	1131	1142	intensified
O	1143	1153	epirubicin
O	1154	1165	monotherapy
O	1166	1169	can
O	1170	1172	be
O	1173	1175	as
O	1176	1185	effective
O	1186	1188	as
O	1189	1190	7
O	1191	1197	cycles
O	1198	1200	of
O	1201	1209	standard
O	1210	1220	sequential
O	1221	1237	polychemotherapy
O	1238	1240	in
O	1241	1245	high
O	1245	1246	-
O	1246	1250	risk
O	1251	1257	breast
O	1258	1264	cancer
O	1265	1273	patients
O	1274	1278	with
O	1279	1280	>
O	1281	1283	or
O	1284	1285	=
O	1285	1287	10
O	1288	1296	positive
O	1297	1302	lymph
O	1303	1308	nodes
O	1308	1309	,
O	1310	1317	despite
O	1318	1327	treatment
O	1328	1332	with
O	1333	1334	a
O	1335	1341	single
O	1342	1347	agent
O	1348	1351	and
O	1352	1353	a
O	1354	1361	shorter
O	1362	1371	treatment
O	1372	1380	duration
O	1380	1381	.
